Truist Financial Corp Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Truist Financial Corp lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 12.4% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 29,942 shares of the medical research company’s stock after selling 4,250 shares during the period. Truist Financial Corp owned 0.06% of Charles River Laboratories International worth $5,527,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Empirical Finance LLC lifted its holdings in Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after buying an additional 53 shares during the period. Fiduciary Financial Group LLC lifted its holdings in Charles River Laboratories International by 3.9% in the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after buying an additional 63 shares during the period. Pinnacle Bancorp Inc. lifted its holdings in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares during the period. M&T Bank Corp lifted its holdings in Charles River Laboratories International by 3.4% in the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after buying an additional 66 shares during the period. Finally, Covestor Ltd lifted its holdings in Charles River Laboratories International by 40.9% in the third quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock worth $65,000 after buying an additional 95 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO James C. Foster bought 6,075 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Price Performance

Shares of CRL opened at $163.11 on Friday. The company has a market capitalization of $8.34 billion, a P/E ratio of 1,087.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average of $172.84 and a 200 day moving average of $188.09. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the previous year, the firm posted $2.46 EPS. The firm’s revenue was down 1.1% on a year-over-year basis. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on CRL shares. The Goldman Sachs Group lowered their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Bank of America lowered their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. UBS Group reiterated a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, Charles River Laboratories International currently has an average rating of “Hold” and an average target price of $195.71.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).